Evidence map›Paper›PMID 24625778›Full record

ArticleNature protocols2014

Germline transgenesis in rodents by pronuclear microinjection of Sleeping Beauty transposons.

Zoltán Ivics, Lajos Mátés, Tien Yin Yau, Vladimír Landa, Vaclav Zidek, Sanum Bashir, Orsolya I Hoffmann, László Hiripi, Wiebke Garrels, Wilfried A Kues and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature protocols, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 3 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 5 countries.

Zoltán IvicsDivision of Medical Biotechnology, Paul Ehrlich Institute, Langen, Germany.
Lajos MátésBiological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary.
Tien Yin YauInstitute of Laboratory Animal Science, University of Veterinary Medicine Vienna, Vienna, Austria.
Vladimír LandaInstitute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
Vaclav ZidekInstitute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
Sanum BashirMax Delbrück Center for Molecular Medicine, Berlin, Germany.
Orsolya I HoffmannAgricultural Biotechnology Center, Gödöllö, Hungary.
László HiripiAgricultural Biotechnology Center, Gödöllö, Hungary.
Wiebke GarrelsFriedrich Loeffler Institut, Institut für Nutztiergenetik, Neustadt, Germany.
Wilfried A KuesFriedrich Loeffler Institut, Institut für Nutztiergenetik, Neustadt, Germany.
Zsuzsanna BöszeAgricultural Biotechnology Center, Gödöllö, Hungary.
Aron GeurtsDepartment of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Michal PravenecInstitute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
Thomas RülickeInstitute of Laboratory Animal Science, University of Veterinary Medicine Vienna, Vienna, Austria.ORCID 0000000221219496
Zsuzsanna IzsvákMax Delbrück Center for Molecular Medicine, Berlin, Germany.
Agricultural Biotechnology Institute · HUCzech Academy of Sciences · CZFriedrich-Loeffler-Institut · DEMax Delbrück Center · DEUniversity of Veterinary Medicine Vienna · ATHUN-REN Szegedi Biológiai Kutatóközpont · HUMedical College of Wisconsin · USPaul Ehrlich Institut · DE

Funding

Advanced genetic engineering technology developmentDP2OD008396 · OD · MEDICAL COLLEGE OF WISCONSIN · PI GEURTS, ARON M · 2011 to 2011
$2.3M
NIH HHS DP2 OD008396
6 · The paper itself

Abstract

We describe a protocol for high-efficiency germline transgenesis and sustained transgene expression in two important biomedical models, the mouse and the rat, by using the Sleeping Beauty transposon system. The procedure is based on co-injection of synthetic mRNA encoding the SB100X hyperactive transposase, together with circular plasmid DNA carrying a transgene construct flanked by binding sites for the transposase, into the pronuclei of fertilized oocytes. Upon translation of the transposase mRNA, enzyme-mediated excision of the transgene cassettes from the injected plasmids followed by permanent genomic insertion produces stable transgenic animals. Generation of a germline-transgenic founder animal by using this protocol takes ∼3 months. Transposon-mediated transgenesis compares favorably in terms of both efficiency and reliable transgene expression with classic pronuclear microinjection, and it offers comparable efficacies to lentiviral approaches without limitations on vector design, issues of transgene silencing, and the toxicity and biosafety concerns of working with viral vectors.

Indexed as

Animals, Genetically ModifiedDNA Transposable ElementsGene Transfer TechniquesAnimalsBinding SitesFemaleGerm CellsMaleMiceMice, Inbred C57BLMice, TransgenicMicroinjectionsRatsRats, Inbred F344Rats, TransgenicRodentiaDNA Transposable ElementsTransposases

Identifiers

PMID24625778
OpenAlexW4231139321

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.